Celldex Therapeutics (NASDAQ:CLDX – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They currently have a $64.00 price target on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 96.69% from the stock’s previous close. […]

HC Wainwright reissued their buy rating on shares of Celldex Therapeutics (NASDAQ:CLDX – Free Report) in a report released on Friday,Benzinga reports. The firm currently has a $64.00 price objective on the biopharmaceutical company’s stock. Other equities research analysts have also recently issued reports about the company. Morgan Stanley boosted their price objective on Celldex […]